GLP-1 & METABOLIC RESEARCHRESEARCH PRODUCT INFORMATION · WHATSAPP CONTACT
manax.
ProductsBrandingPricingReferencesJournalAbout manaxContact manax
JOURNAL / Testing & COA

Semaglutide and tirzepatide: what a method must demonstrate

Using RP-HPLC does not make two analytical procedures equivalent. Suitability needs evidence for the intended measurement. Different molecules also do not, by themselves, prove that one method can never serve both.

KEY POINT

Judge a method against its intended purpose and validation evidence.

Define the intended measurement

Identity, assay and impurity analysis are different tasks. ICH Q2(R2) addresses validation characteristics such as specificity/selectivity, range, accuracy and precision in relation to intended use. A method name should be read together with its sample and analytical purpose.

Sources [1]

The technique name does not define the validated scope

“RP-HPLC” names a technique, not its demonstrated separation capability or scope. Applying a procedure to another substance, matrix or reporting purpose requires assessing coverage of the evidence. Q14 provides scientific and risk-based development principles rather than judging validity from a molecule’s name alone.

Sources [2]

Read each analytical file on its own terms

For semaglutide and tirzepatide, record each analytical purpose, method version, reference standard and validated scope before comparing results. A shared procedure may be justified by suitable evidence. Sharing only a technique name or a purity statement does not supply that evidence.

Sources [1][2]

Original sources

  1. FDA / ICH: Q2(R2) Validation of Analytical Procedures
  2. FDA / ICH: Q14 Analytical Procedure Development

These notes explain public references; they do not replace sample-specific testing or case-specific professional judgment.

Back to the journalBack to top ↑

Scan to contact manax

WhatsApp 二维码,扫码联系 manax

Scan with WhatsApp, then review and send your message.

Save QR code

Saved products

Saved items stay in this browser.